NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)

By All, NexImmune

Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) — NexImmune, a clinical-stage biotechnology company developing…

Read More